Lv2
200 积分 2022-09-21 加入
One Pivotal Trial, the New Default Option for FDA Approval — Ending the Two-Trial Dogma
1个月前
已完结
In-use stability studies: guidelines and challenges
1个月前
已完结
Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer
3个月前
已完结
单抗药物 N-糖基化修饰对结构功能影响及相关药学问题考量
3个月前
已完结